Importantly, these associations were observed in absence of Alzheimer’s disease pathology and beyond GM loss, suggesting that plasma levels of VAMP2 and GFAP may reflect early synaptic alterations, not specific to Alzheimer’s disease and prior to substantial neurodegeneration. This evidence concerns the gene GFAP and early-onset autosomal dominant Alzheimer disease.